Phase 3CompletedAge-related condition
Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older
A 2-year Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Administered Either Annually at Randomization and 12 Months, or Administered at Randomization Only in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia
- Sponsor
- Novartis Pharmaceuticals (Industry)
- Enrollment
- 581 enrolled
- Conditions
- Osteopenia
- Interventions
- Zoledronic Acid; Placebo
- Ages
- adults, older adults
- Registry
- NCT00132808
Full record on ClinicalTrials.gov
From the registry
Osteoporosis prevention is important in patients with osteopenia (low bone density). This study will test the safety and efficacy of zoledronic acid in patients diagnosed with osteopenia.
Primary outcomes
- Percentage Change in Lumbar Spine Bone Mineral Density (BMD) at Month 24 Relative to Baseline, by Stratum
History
Last registry update
Results first posted
Primary completion
Registered
Started